Yestar Healthcare Holdings Company Limited announced that, based on the preliminary review and assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2017, the Group is expected to record an increase of not less than 25% in its consolidated net profit of the Group for the year ended 31 December 2017 as compared with that of the year ended 31 December 2016. The board of directors of the Company wishes to inform the shareholders of the Company (the ''Shareholders'') and the potential investors that, based on the preliminary review and assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2017, the Group is expected to record an increase of not less than 25% in its consolidated net profit of the Group for the year ended 31 December 2017 as compared with that of the year ended 31 December 2016 (audited consolidated net profit of the Group for the year ended 31 December 2016 amounted to approximately RMB 269,928,000). The substantial increase is mainly attributable to (1) the outstanding performance of In Vitro Diagnostic business and (2) the consolidation of financial information of all non-wholly-owned subsidiaries of the Company upon completion of these acquisitions.